IDXX vs INCY: fair value comparison
IDEXX Laboratories, Inc. and Incyte Corporation · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, IDXX currently sits closer to the top of our discount ranking. INCY carries the stronger quality grade.
| IDXX | INCY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $554.99 | $124.37 |
| 12-month range | $559.07–$728.97 | $85.98–$119.52 |
| Sector rank | #30 of 113 Healthcare | #35 of 113 Healthcare |
| Quality grade | B | A |
| Momentum grade | — | A |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Uptrend |
| DCF cross-check | — | Overvalued |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: IDXX fair value analysis · INCY fair value analysis